ORIGINAL RESEARCH

Changes in plasma sphingolipid levels against the background of lipid-lowering therapy in patients with premature atherosclerosis

About authors

1 Central State Medical Academy of the Department of Presidential Affairs of the Russian Federation, Moscow, Russia

2 City Clinical Hospital № 51, Moscow, Russia

3 Institute of Biochemical Physics named after N. M. Emanuel, Moscow, Russia

4 Lomonosov Moscow State University, Moscow, Russia

Correspondence should be addressed: Larisa O. Minushkina
Marshala Timoshenko, 19, str. 1А, Moscow, 121359; ur.liam@anikhsunim

About paper

Funding: RFBR grant 19-04-00870А, Sphingolipidome Analysis of Cardiovascular Disease Markers.

Author contribution: Rogozhina AA — sampling, data acquisition; Alessenko AV — project management; Kurochkin IN — data analysis; Minushkina LO — data analysis, manuscript writing; Gutner UA, Shupik MA, Maloshitskaya OA — sample preparation, laboratory tests, data analysis; Lebedev AT, Zateyshchikov DA — study planning, data analysis, manuscript editing.

Compliance with ethical standards: the study was approved by the Ethics Committee of City Clinical Hospital № 51, Moscow (protocol № 02/19 dated February 7, 2019). Informed consent was submitted by all patients.

Received: 2021-05-24 Accepted: 2021-06-13 Published online: 2021-06-23
|
Figure. Study protocol
Table 1. Dynamic changes in lipid levels in the studied groups
Note: SPN — sphingosine, SPH — sphingonine, S1P — sphingosine-1-phosphate.
Table 2. Dynamic changes of the lipidome in the studied groups
Table 3. Correlation analysis of dynamic changes with baseline levels of LDL-C, HDL-C, and dynamic changes of LDL-C